Oxervate

Active Ingredient(s): Cenegermin-bkbj
FDA Approved: * August 22, 2018
Pharm Company: * DOMPE FARMACEUTICI
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Oxervate Overview

Cenegermin (planned brand names Oxervate, Sentinel), also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). It was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults on 6 July 2017.[2][3][1] As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75NTR) which ...

Read more Oxervate Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cenegermin

Recent Oxervate Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Oxervate: (1 result)

Sorted by National Drug Code

• 71981-020 Oxervate 20 ug/ml Ophthalmic Solution/ Drops by Dompé Farmaceutici S.p.a.

Other drugs which contain Cenegermin-bkbj or a similar ingredient: (1 result)

• CENEGERMIN